In an ageing population with an increased disease burden, clinicians are seeking ways to manage glaucoma patients routinely presenting in already busy practices. One of these clinicians, Dr Jed Lusthaus, a glaucoma specialist at Sydney Eye Hospital and director of Eyehaus, is tackling these challenges by using an integrated, multi-modality approach to overlay and associate raw data from diagnostic devices when managing his patients.
Glaucoma Australia (GA) has launched a new initiative encouraging Australians to share a photo of “an amazing sight” every day for seven days to raise funds during World Glaucoma Week (6–12 March 2022). Read more
The inventors of a new rapid screening test for glaucoma that could help advance early detection of the disease are seeking a commercial partner ahead of a clinical trial planned for 2022. Read more
Adelaide researchers have published the world’s first study documenting the lived experience of childhood glaucoma in adults, which they hope will lead to a first-of-its-kind quality of life (QoL) tool for the rare condition. Read more
A UNSW researcher from the university’s Graduate School of Biomedical Engineering has been awarded Glaucoma Australia (GA)’s ‘Quinlivan’ Research Grant to develop a novel imaging technology for the early detection and monitoring of glaucoma. Read more
An orthoptic-led glaucoma clinic at the Sydney Eye Hospital that is managing low risk and stable patients is helping to drive major efficiencies, write MELANIE LAI and CHRISTINA PETERSON.
Australian company Nova Eye Medical has completed a transaction with a US company to acquire a portfolio of patents related to glaucoma treatments. Read more
Designs For Vision is now supplying the iCare HOME2 tonometer, which it says revolutionises glaucoma care by enabling patients to capture their own intraocular pressure (IOP) at different times of the day and night.
Australian researchers have led the development of a promising new genetic test for glaucoma that can potentially identify 15-times more people at high risk of glaucoma than an existing genetic test. Read more
Glaucoma Australia (GA) has opened the applications period for its annual ‘Quinlivan’ Research Grants program, with a funding pool of up to $200,000 this year. Read more
Glaukos has secured Australian regulatory approval for the Preserflo MicroShunt, offering late-stage glaucoma patients a more elegant surgical alternative to conventional filtration procedures. Read more
Glaucoma Australia (GA) has appointed Ms Maree O’Brien as its new president who will replace the outgoing Associate Professor Simon Skalicky who has served the charity organisation for the past seven years. Read more
As part of the orthoptic team at the Royal Brisbane and Women’s Hospital (RBWH), I’m part of a multidisciplinary eye healthcare team, caring for patients with various ocular and systemic health issues. Read more
Glaucoma Australia (GA) has launched a new family-focused awareness campaign called ‘Begins With You’, to mobilise people diagnosed with glaucoma to ask their family, and friends over the age of 50 to get their eyes tested. Read more
Latanoprost was a game-changing glaucoma therapy and still remains a go-to treatment for many ophthalmologists more than two decades later. PROFESSOR JOHN GRIGG – an investigator on an important clinical trial for the drug in 1996 – traces its history and explains how it fits into the treatment algorithm today.
The pathway for glaucoma suspects isn’t always clear cut with many maintaining this classification for prolonged periods. A major eyecare provider outlines its efforts to keep on top of this group, underpinned by a robust communications strategy.
Australian researchers have been at the fore of the largest genetic study of glaucoma that has identified 44 new genetic variants that may lead to new treatment targets. Read more
Melbourne glaucoma researcher Dr Jennifer Fan Gaskin is one of 60 women selected for Science & Technology Australia’s Superstars of STEM program, which aims to challenge gender assumptions about scientists and increase female visibility in their relevant field. Read more
Medicinal cannabis is often presented as an alternative treatment for glaucoma. Although there is evidence that cannabis lowers intraocular pressure, its role as a viable glaucoma therapy is limited by a short duration of action, psychotropic effects, and possible tachyphylaxis.
A Victorian biopharmaceutical company has reported positive results from a Phase 1 study examining the safety of its biodegradable implant for glaucoma. Read more